神经科

订阅

MedSci主页 / 所有栏目 / 神经科

[AAIC 2012]tau抗体药物EpoD有助防治阿尔茨海默病

2012-07-30 陈蓉 生物谷

AAIC2012阿尔茨海默病epithiloneDTau抗体药物
关注

       2012年阿尔茨海默病协会主办的国际会议上，来自美国宾夕法尼亚大学医学院的研究人员报道，一种被称作epithilone D(EpoD)的tau抗体药物能够有效地在动物模型中防治阿尔茨海默病的发展，改善神经元功能和认知，同时降低tau病理特征。        通过靶向tau，这种抗体药物旨在让微管保持

       2012年阿尔茨海默病协会主办的国际会议上，来自美国宾夕法尼亚大学医学院的研究人员报道，一种被称作epithilone D(EpoD)的tau抗体药物能够有效地在动物模型中防治阿尔茨海默病的发展，改善神经元功能和认知，同时降低tau病理特征。

       通过靶向tau，这种抗体药物旨在让微管保持稳定，从而有助于促进必需营养物质和信息在细胞之间进行传输。当tau不起作用时，微管破裂，而且tau堆积而形成纤维缠结。宾夕法尼亚大学佩雷尔曼医学院病理学与临床医学教授John Trojanowski博士说，“在动物模型中，这种药物通过矫正tau功能丧失从而让微管保持稳定和弥补因形成神经原纤维缠结(neurofibrillary tangle)而造成的tau丢失，这就表明该药物有效地攻击靶标tau，同时还提示着调控阿尔茨海默病和其他基于tau 的神经退化疾病中的tau功能将可能成为一种重要的治疗选择。除了靶向淀粉样蛋白的药物---它们可能在晚期阿尔茨海默病中不能发挥作用---之外，我们希望这种药物和其他tau抗体药物能够在阿尔茨海默病患者体内进行测试以便确定让发生功能障碍的tau蛋白破坏的微管稳定化是否可能能够改变患者的临床结果和病理结果。”

       在此之前，研究人员已证实这种药物能够阻止动物模型中的进一步神经损伤和改善认知。相关结果发表在Journal of Neuroscience期刊上[J Neurosci. 2010 Oct 13;30(41):13861-6.]。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1816536, encodeId=848b181653698, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Jun 24 06:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817559, encodeId=1aaf181e55935, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 14 01:54:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722675, encodeId=96031e2267500, content=<a href='/topic/show?id=720216e075' target=_blank style='color:#2F92EE;'>#AAIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1670, encryptionId=720216e075, topicName=AAIC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46033300854, createdName=hywen7337, createdTime=Mon Jun 24 19:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957590, encodeId=f3fb195e590f0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Jun 26 19:54:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016143, encodeId=8c35201614388, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 15 16:54:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4609, encodeId=e0c4460940, content=This makes everything so copmleetly painless., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gleuber, createdTime=Sat Aug 11 06:26:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469913, encodeId=d1091469913b7, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509244, encodeId=e01c150924405, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598451, encodeId=2b951598451d9, content=<a href='/topic/show?id=a4d91e14975' target=_blank style='color:#2F92EE;'>#Tau抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17149, encryptionId=a4d91e14975, topicName=Tau抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=)]
    2013-06-24 ms1948154235210413

    #阿尔茨#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1816536, encodeId=848b181653698, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Jun 24 06:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817559, encodeId=1aaf181e55935, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 14 01:54:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722675, encodeId=96031e2267500, content=<a href='/topic/show?id=720216e075' target=_blank style='color:#2F92EE;'>#AAIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1670, encryptionId=720216e075, topicName=AAIC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46033300854, createdName=hywen7337, createdTime=Mon Jun 24 19:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957590, encodeId=f3fb195e590f0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Jun 26 19:54:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016143, encodeId=8c35201614388, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 15 16:54:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4609, encodeId=e0c4460940, content=This makes everything so copmleetly painless., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gleuber, createdTime=Sat Aug 11 06:26:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469913, encodeId=d1091469913b7, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509244, encodeId=e01c150924405, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598451, encodeId=2b951598451d9, content=<a href='/topic/show?id=a4d91e14975' target=_blank style='color:#2F92EE;'>#Tau抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17149, encryptionId=a4d91e14975, topicName=Tau抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=)]
    2013-05-14 12498da4m32(暂无昵称)

    #阿尔茨海#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1816536, encodeId=848b181653698, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Jun 24 06:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817559, encodeId=1aaf181e55935, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 14 01:54:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722675, encodeId=96031e2267500, content=<a href='/topic/show?id=720216e075' target=_blank style='color:#2F92EE;'>#AAIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1670, encryptionId=720216e075, topicName=AAIC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46033300854, createdName=hywen7337, createdTime=Mon Jun 24 19:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957590, encodeId=f3fb195e590f0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Jun 26 19:54:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016143, encodeId=8c35201614388, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 15 16:54:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4609, encodeId=e0c4460940, content=This makes everything so copmleetly painless., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gleuber, createdTime=Sat Aug 11 06:26:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469913, encodeId=d1091469913b7, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509244, encodeId=e01c150924405, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598451, encodeId=2b951598451d9, content=<a href='/topic/show?id=a4d91e14975' target=_blank style='color:#2F92EE;'>#Tau抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17149, encryptionId=a4d91e14975, topicName=Tau抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=)]
    2013-06-24 hywen7337

    #AAIC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1816536, encodeId=848b181653698, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Jun 24 06:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817559, encodeId=1aaf181e55935, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 14 01:54:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722675, encodeId=96031e2267500, content=<a href='/topic/show?id=720216e075' target=_blank style='color:#2F92EE;'>#AAIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1670, encryptionId=720216e075, topicName=AAIC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46033300854, createdName=hywen7337, createdTime=Mon Jun 24 19:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957590, encodeId=f3fb195e590f0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Jun 26 19:54:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016143, encodeId=8c35201614388, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 15 16:54:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4609, encodeId=e0c4460940, content=This makes everything so copmleetly painless., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gleuber, createdTime=Sat Aug 11 06:26:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469913, encodeId=d1091469913b7, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509244, encodeId=e01c150924405, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598451, encodeId=2b951598451d9, content=<a href='/topic/show?id=a4d91e14975' target=_blank style='color:#2F92EE;'>#Tau抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17149, encryptionId=a4d91e14975, topicName=Tau抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=)]
    2013-06-26 12498e5fm12(暂无昵称)

    #抗体药#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1816536, encodeId=848b181653698, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Jun 24 06:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817559, encodeId=1aaf181e55935, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 14 01:54:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722675, encodeId=96031e2267500, content=<a href='/topic/show?id=720216e075' target=_blank style='color:#2F92EE;'>#AAIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1670, encryptionId=720216e075, topicName=AAIC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46033300854, createdName=hywen7337, createdTime=Mon Jun 24 19:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957590, encodeId=f3fb195e590f0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Jun 26 19:54:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016143, encodeId=8c35201614388, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 15 16:54:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4609, encodeId=e0c4460940, content=This makes everything so copmleetly painless., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gleuber, createdTime=Sat Aug 11 06:26:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469913, encodeId=d1091469913b7, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509244, encodeId=e01c150924405, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598451, encodeId=2b951598451d9, content=<a href='/topic/show?id=a4d91e14975' target=_blank style='color:#2F92EE;'>#Tau抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17149, encryptionId=a4d91e14975, topicName=Tau抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=)]
    2012-12-15 zhouqu_8

    #抗体药物#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1816536, encodeId=848b181653698, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Jun 24 06:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817559, encodeId=1aaf181e55935, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 14 01:54:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722675, encodeId=96031e2267500, content=<a href='/topic/show?id=720216e075' target=_blank style='color:#2F92EE;'>#AAIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1670, encryptionId=720216e075, topicName=AAIC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46033300854, createdName=hywen7337, createdTime=Mon Jun 24 19:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957590, encodeId=f3fb195e590f0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Jun 26 19:54:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016143, encodeId=8c35201614388, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 15 16:54:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4609, encodeId=e0c4460940, content=This makes everything so copmleetly painless., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gleuber, createdTime=Sat Aug 11 06:26:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469913, encodeId=d1091469913b7, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509244, encodeId=e01c150924405, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598451, encodeId=2b951598451d9, content=<a href='/topic/show?id=a4d91e14975' target=_blank style='color:#2F92EE;'>#Tau抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17149, encryptionId=a4d91e14975, topicName=Tau抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=)]
    2012-08-11 gleuber

    This makes everything so copmleetly painless.

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1816536, encodeId=848b181653698, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Jun 24 06:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817559, encodeId=1aaf181e55935, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 14 01:54:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722675, encodeId=96031e2267500, content=<a href='/topic/show?id=720216e075' target=_blank style='color:#2F92EE;'>#AAIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1670, encryptionId=720216e075, topicName=AAIC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46033300854, createdName=hywen7337, createdTime=Mon Jun 24 19:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957590, encodeId=f3fb195e590f0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Jun 26 19:54:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016143, encodeId=8c35201614388, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 15 16:54:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4609, encodeId=e0c4460940, content=This makes everything so copmleetly painless., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gleuber, createdTime=Sat Aug 11 06:26:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469913, encodeId=d1091469913b7, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509244, encodeId=e01c150924405, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598451, encodeId=2b951598451d9, content=<a href='/topic/show?id=a4d91e14975' target=_blank style='color:#2F92EE;'>#Tau抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17149, encryptionId=a4d91e14975, topicName=Tau抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=)]
    2012-08-01 yhj-time

    #阿尔茨海默#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1816536, encodeId=848b181653698, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Jun 24 06:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817559, encodeId=1aaf181e55935, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 14 01:54:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722675, encodeId=96031e2267500, content=<a href='/topic/show?id=720216e075' target=_blank style='color:#2F92EE;'>#AAIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1670, encryptionId=720216e075, topicName=AAIC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46033300854, createdName=hywen7337, createdTime=Mon Jun 24 19:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957590, encodeId=f3fb195e590f0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Jun 26 19:54:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016143, encodeId=8c35201614388, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 15 16:54:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4609, encodeId=e0c4460940, content=This makes everything so copmleetly painless., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gleuber, createdTime=Sat Aug 11 06:26:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469913, encodeId=d1091469913b7, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509244, encodeId=e01c150924405, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598451, encodeId=2b951598451d9, content=<a href='/topic/show?id=a4d91e14975' target=_blank style='color:#2F92EE;'>#Tau抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17149, encryptionId=a4d91e14975, topicName=Tau抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=)]
    2012-08-01 szhvet

    #Tau#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1816536, encodeId=848b181653698, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Jun 24 06:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817559, encodeId=1aaf181e55935, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 14 01:54:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722675, encodeId=96031e2267500, content=<a href='/topic/show?id=720216e075' target=_blank style='color:#2F92EE;'>#AAIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1670, encryptionId=720216e075, topicName=AAIC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46033300854, createdName=hywen7337, createdTime=Mon Jun 24 19:54:00 CST 2013, time=2013-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957590, encodeId=f3fb195e590f0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Jun 26 19:54:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016143, encodeId=8c35201614388, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Dec 15 16:54:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4609, encodeId=e0c4460940, content=This makes everything so copmleetly painless., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gleuber, createdTime=Sat Aug 11 06:26:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469913, encodeId=d1091469913b7, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509244, encodeId=e01c150924405, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598451, encodeId=2b951598451d9, content=<a href='/topic/show?id=a4d91e14975' target=_blank style='color:#2F92EE;'>#Tau抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17149, encryptionId=a4d91e14975, topicName=Tau抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Aug 01 03:54:00 CST 2012, time=2012-08-01, status=1, ipAttribution=)]
    2012-08-01 医者仁心

    #Tau抗体药物#

    0